盟科药业(688373)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688373 盟科药业

已收盘 12-23 15:00:00

{"stockData":{"symbol":"688373","market":"SH","secType":"STK","nameCN":"盟科药业","latestPrice":5.13,"timestamp":1734937200000,"preClose":5.56,"halted":0,"volume":13274546,"delay":0,"floatShares":366000000,"shares":655000000,"eps":-0.7143,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.43,"latestTime":"12-23 15:00:00","open":5.51,"high":5.58,"low":5.09,"amount":69783600,"amplitude":0.0881,"askPrice":5.14,"askSize":140,"bidPrice":5.13,"bidSize":523,"shortable":0,"etf":0,"ttmEps":-0.7143,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1735003800000},"adr":0,"adjPreClose":5.56,"symbolType":"stock_kcb","openAndCloseTimeList":[[1734917400000,1734924600000],[1734930000000,1734937200000]],"highLimit":6.12,"lowLimit":5,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":655210084,"pbRate":5.92,"roa":"--","roe":"--","epsLYR":-0.64,"committee":0.325812,"marketValue":3361000000,"floatMarketCap":1876000000,"peRate":-7.181857,"changeRate":-0.0773,"turnoverRate":0.0363,"status":1,"afterMarket":{"amount":0,"volume":0,"close":5.13,"buyVolume":0,"sellVolume":0,"time":1734939238975,"indexStatus":"已收盘 12-23 15:30:00","preClose":5.56}},"requestUrl":"/m/hq/s/688373/wiki","defaultTab":"wiki","newsList":[{"id":"2493650277","title":"盟科药业-U跌5% 近半年1券商买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2493650277","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493650277?lang=zh_cn&edition=full","pubTime":"2024-12-23 09:41","pubTimestamp":1734918076,"startTime":"0","endTime":"0","summary":"12月23日，盟科药业-U股价大幅下跌，截至09点41分，盟科药业-U下跌5.04%，报5.28元/股，成交1410万元，换手率0.71%，振幅5.40%。资金动向截止发稿，盟科药业-U获得主力净流入109万元，其中超大单流入54万元，大单流入54万元。融资融券方面，盟科药业-U12月20日获得融资净买入82万元，当日该股融资余额为4108万元，当较前一日增加2.05%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241223094128ab8c90dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241223094128ab8c90dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688373"],"gpt_icon":0},{"id":"2492641709","title":"盟科药业-U大跌 获1家券商买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2492641709","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492641709?lang=zh_cn&edition=full","pubTime":"2024-12-17 13:12","pubTimestamp":1734412357,"startTime":"0","endTime":"0","summary":"12月17日，盟科药业-U股价大幅下跌，截至13点12分，盟科药业-U下跌5.18%，报5.68元/股，成交4112万元，换手率1.92%，振幅6.84%。资金动向截止发稿，盟科药业-U获得主力净流出688万元，其中超大单流出115万元，大单流出572万元。融资融券方面，盟科药业-U12月13日获得融资净买入44万元，当日该股融资余额为4067万元，当较前一日增加1.10%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121713124495ea2557&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121713124495ea2557&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2491301528","title":"盟科药业-U大跌 获1家券商买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2491301528","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491301528?lang=zh_cn&edition=full","pubTime":"2024-12-13 14:51","pubTimestamp":1734072664,"startTime":"0","endTime":"0","summary":"12月13日，盟科药业-U股价大幅下跌，截至14点51分，盟科药业-U下跌5.28%，报6.10元/股，成交4986万元，换手率2.18%，振幅4.81%。资金动向截止发稿，盟科药业-U获得主力净流出857万元，其中超大单流出257万元，大单流出598万元。主营业务及业绩盟科药业-U公司主营业务为一家以治疗感染性疾病为核心，拥有全球自主知识产权和国际竞争力的创新药企业，致力于发现、开发和商业化针对未满足临床需求的创新药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213145117984bbdd1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213145117984bbdd1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2490487218","title":"盟科药业(688373.SH)：全新包装规格单盒12片装康替唑胺片即将上市销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2490487218","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490487218?lang=zh_cn&edition=full","pubTime":"2024-12-12 17:14","pubTimestamp":1733994843,"startTime":"0","endTime":"0","summary":"智通财经APP讯，盟科药业(688373.SH)发布公告，公司近日推出全新包装规格的单盒12片装康替唑胺片并即将启动上市销售。此次新包装规格产品将探索通过代理销售模式，旨在借力外部资源和代理商市场触达优势，快速开拓更多区域市场。康替唑胺片是公司自主研发的具有全球知识产权的恶唑烷酮类1类抗菌新药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1224031.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2490872600","title":"盟科药业：新包装规格康替唑胺片即将上市销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2490872600","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490872600?lang=zh_cn&edition=full","pubTime":"2024-12-12 17:10","pubTimestamp":1733994632,"startTime":"0","endTime":"0","summary":"盟科药业公告，公司推出全新包装规格的单盒12片装康替唑胺片，并即将启动上市销售。新包装规格产品将探索通过代理销售模式，借力外部资源和代理商市场触达优势，快速开拓更多区域市场。康替唑胺片是公司自主研发的具有全球知识产权的恶唑烷酮类1类抗菌新药，已于2021年6月1日获NMPA批准用于治疗复杂性皮肤和软组织感染，为全球首次获批上市。未来产品销售及收入存在不确定性，敬请投资者谨慎决策，注意投资风险。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121200027582.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2490103829","title":"盟科药业（688373）12月9日主力资金净卖出1251.92万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490103829","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490103829?lang=zh_cn&edition=full","pubTime":"2024-12-10 08:21","pubTimestamp":1733790075,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年12月9日收盘，盟科药业报收于6.28元，下跌4.56%，换手率4.27%，成交量15.61万手，成交额9929.94万元。近5日资金流向一览见下表：盟科药业融资融券信息显示，融资方面，当日融资买入703.22万元，融资偿还555.81万元，融资净买入147.42万元，连续3日净买入累计330.48万元。盟科药业主营业务：以治疗感染性疾病为核心,拥有全球自主知识产权和国际竞争力的创新药企业,致力于发现、开发和商业化针对未满足临床需求的创新药物。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121000008935.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688373"],"gpt_icon":0},{"id":"2490797246","title":"盟科药业-U大跌 近半年2券商买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2490797246","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490797246?lang=zh_cn&edition=full","pubTime":"2024-12-09 13:05","pubTimestamp":1733720759,"startTime":"0","endTime":"0","summary":"12月09日，盟科药业-U股价大幅下跌，截至13点05分，盟科药业-U下跌5.02%，报6.25元/股，成交6285万元，换手率2.68%，振幅5.78%。此外，数据统计显示，近半年内2家券商给予买入建议。资金动向截止发稿，盟科药业-U获得主力净流出598万元，其中超大单流出240万元，大单流出356万元。融资融券方面，盟科药业-U12月06日获得融资净买入83万元，当日该股融资余额为4021万元，当较前一日增加2.13%，实现2连增。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241209130607ab68daa0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241209130607ab68daa0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2490769664","title":"【机构调研记录】申万菱信基金调研盟科药业","url":"https://stock-news.laohu8.com/highlight/detail?id=2490769664","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490769664?lang=zh_cn&edition=full","pubTime":"2024-12-09 08:02","pubTimestamp":1733702525,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及12月6日披露的机构调研信息，申万菱信基金近期对1家上市公司进行了调研，相关名单如下：1）盟科药业 个股亮点：公司抗革兰阴性耐药菌新药MRX-8开展的首个人体I期临床试验已完成。申万菱信基金成立于2004年，截至目前，资产管理规模906.03亿元，排名64/208；资产管理规模791.33亿元，排名55/208；管理公募基金数151只，排名46/208；旗下公募基金经理27人，排名46/208。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120900001154.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2489435408","title":"盟科药业12月5日现3笔大宗交易 成交金额503万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2489435408","media":"新浪证券-红岸工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489435408?lang=zh_cn&edition=full","pubTime":"2024-12-05 17:40","pubTimestamp":1733391600,"startTime":"0","endTime":"0","summary":"　　12月5日，盟科药业收涨1.92%，收盘价为6.38元，发生3笔大宗交易，合计成交量100万股，成交金额503万元。　　第2笔成交价格为5.03元，成交40.00万股，成交金额201.20万元，溢价率为-21.16%，买方营业部为机构专用，卖方营业部为华泰证券股份有限公司北京分公司。　　进一步统计，近3个月内该股累计发生18笔大宗交易，合计成交金额为3982万元。该股近5个交易日累计上涨19.70%，主力资金合计净流入1963.08万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2024-12-05/doc-incymcmq9729582.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2489048047","title":"12月5日盟科药业现3笔折价21.16%的大宗交易 合计成交503万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2489048047","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489048047?lang=zh_cn&edition=full","pubTime":"2024-12-05 17:20","pubTimestamp":1733390434,"startTime":"0","endTime":"0","summary":"证券之星消息，12月5日盟科药业发生大宗交易，交易数据如下：近三个月该股共发生18笔大宗交易，合计成交9.7万手，折价成交18笔。该股在过去半年内已有共计1860.44万股限售解禁股上市，占公司总股本的2.84%。截至2024年12月5日收盘，盟科药业(688373)报收于6.38元，上涨1.92%，换手率3.12%，成交量11.41万手，成交额7230.05万元。该股最近90天内共有1家机构给出评级，买入评级1家。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120500029422.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2488415221","title":"12月4日盟科药业现1笔折价19.65%的大宗交易 合计成交150.9万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2488415221","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488415221?lang=zh_cn&edition=full","pubTime":"2024-12-04 17:20","pubTimestamp":1733304043,"startTime":"0","endTime":"0","summary":"证券之星消息，12月4日盟科药业发生大宗交易，交易数据如下：大宗交易成交价格5.03元，相对当日收盘价折价19.65%，成交30万股，成交金额150.9万元，买方营业部为华泰证券股份有限公司北京雍和宫证券营业部，卖方营业部为华泰证券股份有限公司北京分公司。近三个月该股共发生15笔大宗交易，合计成交8.7万手，折价成交15笔。截至2024年12月4日收盘，盟科药业报收于6.26元，下跌0.48%，换手率4.81%，成交量17.6万手，成交额1.12亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120400031468.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688373"],"gpt_icon":0},{"id":"2488999264","title":"盟科药业12月3日现1笔大宗交易 成交金额150.9万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2488999264","media":"新浪证券-红岸工作室","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488999264?lang=zh_cn&edition=full","pubTime":"2024-12-03 17:40","pubTimestamp":1733218800,"startTime":"0","endTime":"0","summary":"　　12月3日，盟科药业收涨1.78%，收盘价为6.29元，发生1笔大宗交易，合计成交量30万股，成交金额150.9万元。　　第1笔成交价格为5.03元，成交30.00万股，成交金额150.90万元，溢价率为-20.03%，买方营业部为东方财富证券股份有限公司拉萨东环路第二证券营业部，卖方营业部为华泰证券股份有限公司北京分公司。　　进一步统计，近3个月内该股累计发生14笔大宗交易，合计成交金额为3328.1万元。该股近5个交易日累计上涨20.73%，主力资金合计净流入1681.64万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2024-12-03/doc-incyerft1592543.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2488996208","title":"12月3日盟科药业现1笔折价20.03%的大宗交易 合计成交150.9万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2488996208","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488996208?lang=zh_cn&edition=full","pubTime":"2024-12-03 17:20","pubTimestamp":1733217623,"startTime":"0","endTime":"0","summary":"证券之星消息，12月3日盟科药业发生大宗交易，交易数据如下：大宗交易成交价格5.03元，相对当日收盘价折价20.03%，成交30万股，成交金额150.9万元，买方营业部为东方财富证券股份有限公司拉萨东环路第二证券营业部，卖方营业部为华泰证券股份有限公司北京分公司。近三个月该股共发生14笔大宗交易，合计成交8.4万手，折价成交14笔。截至2024年12月3日收盘，盟科药业报收于6.29元，上涨1.78%，换手率6.58%，成交量24.04万手，成交额1.52亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120300031334.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2488629656","title":"12月2日盟科药业现3笔折价18.61%的大宗交易 合计成交503万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2488629656","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488629656?lang=zh_cn&edition=full","pubTime":"2024-12-02 17:20","pubTimestamp":1733131239,"startTime":"0","endTime":"0","summary":"证券之星消息，12月2日盟科药业发生大宗交易，交易数据如下：近三个月该股共发生13笔大宗交易，合计成交8.1万手，折价成交13笔。该股在过去半年内已有共计1860.44万股限售解禁股上市，占公司总股本的2.84%。截至2024年12月2日收盘，盟科药业(688373)报收于6.18元，上涨10.55%，换手率8.83%，成交量32.27万手，成交额1.94亿元。该股最近90天内共有1家机构给出评级，买入评级1家。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120200023066.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2488230376","title":"盟科药业-U12月02日主力资金流出21万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2488230376","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488230376?lang=zh_cn&edition=full","pubTime":"2024-12-02 15:20","pubTimestamp":1733124041,"startTime":"0","endTime":"0","summary":"12月02日, 盟科药业-U股价涨10.55%，报收6.18元，成交金额1.94亿元，换手率8.83%，振幅12.34%，量比2.67。盟科药业-U今日主力资金净流出21万元，连续3日净流出，上一交易日主力净流出190万元，今日环比减少88.95%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为66.67%，平均跌幅为2.85%。该股近5个交易日上涨18.39%，主力资金累计净流出723万元；近20日主力资金累计净流出2228万元，其中净流出天数为12日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202153848abef0a77&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202153848abef0a77&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2488161154","title":"盟科药业创近8月新高获买入建议","url":"https://stock-news.laohu8.com/highlight/detail?id=2488161154","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488161154?lang=zh_cn&edition=full","pubTime":"2024-12-02 09:51","pubTimestamp":1733104272,"startTime":"0","endTime":"0","summary":"12月02日，盟科药业-U股价大幅上涨，截至09点51分，盟科药业-U上涨5.01%，报5.87元/股，创近8个月新高，成交2462万元，换手率1.18%。资金动向截止发稿，盟科药业-U获得主力净流入164万元，其中超大单流入116万元，大单流入48万元。主营业务及业绩盟科药业-U公司主营业务为一家以治疗感染性疾病为核心，拥有全球自主知识产权和国际竞争力的创新药企业，致力于发现、开发和商业化针对未满足临床需求的创新药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202095121a264e937&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202095121a264e937&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2487304519","title":"盟科药业迎医保利好","url":"https://stock-news.laohu8.com/highlight/detail?id=2487304519","media":"智选洞察","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487304519?lang=zh_cn&edition=full","pubTime":"2024-11-29 13:05","pubTimestamp":1732856728,"startTime":"0","endTime":"0","summary":"资金动向截止发稿，盟科药业-U获得主力净流入331万元，其中超大单流入268万元，大单流入62万元。主营业务及业绩盟科药业-U公司主营业务为一家以治疗感染性疾病为核心，拥有全球自主知识产权和国际竞争力的创新药企业，致力于发现、开发和商业化针对未满足临床需求的创新药物。最新财报显示，今年三季报，盟科药业-U实现营业收入9,756.23万元，同比增长42.90%，净利润为-2.91亿元，同比减少19.16%，基本每股收益为-0.44元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241129130843abe7afba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241129130843abe7afba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688373"],"gpt_icon":0},{"id":"2486879573","title":"盟科药业（688373）11月27日主力资金净买入225.29万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2486879573","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486879573?lang=zh_cn&edition=full","pubTime":"2024-11-28 08:20","pubTimestamp":1732753247,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年11月27日收盘，盟科药业报收于5.39元，上涨3.45%，换手率2.43%，成交量8.88万手，成交额4659.07万元。近5日资金流向一览见下表：盟科药业融资融券信息显示，融资方面，当日融资买入408.35万元，融资偿还264.73万元，融资净买入143.63万元。盟科药业主营业务：以治疗感染性疾病为核心,拥有全球自主知识产权和国际竞争力的创新药企业,致力于发现、开发和商业化针对未满足临床需求的创新药物。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112800006411.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2486387128","title":"1-10月医保统筹收入稳增长，机构：医药后市反转源于三大机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2486387128","media":"汇添富基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486387128?lang=zh_cn&edition=full","pubTime":"2024-11-28 08:11","pubTimestamp":1732752682,"startTime":"0","endTime":"0","summary":"消息面上，据医保局日前披露，2024年1-10月医保统筹基金收入23065.07亿元，同比增长8.9%；2024年1-10月统筹支出19165.88亿元，同比增长8.9%。对此，国泰君安表示，1-10月医保统筹基金运行平稳，收入稳健增长，支出增速逐月收窄。国金证券表示，由于多方面因素，医药板块景气度在2021年后经历了长时间的下行。2024年11月7日，国家医保局召开了座谈会，强调了全国统一医保平台和大数据赋能商保发展的重要性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112807590598e4504f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112807590598e4504f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688443","688690","600771","603707","688271","600329","600739","688266","688085","600867","BK0096","605199","688163","688617","688428","600196","600055","BK0012","688105","600422","688029","688062","688626","688067","600572","603896","BK0239","600721","688301","688520","603301","600129","688506","600085","688331","688212","600380","688566","688581","600252","603233","688139","600535","BK0028","603439","603367","603882","688177","688073","688382","600200","603939","688050","688356","688221","600276","603538","688389","688198","600763","600161","688247","603259","600436","688575","603858","603392","688315","688222","600062","688189","688298","600998","600332","688193","688166","603087","600420","BK0070","600976","688670","688202","688046","600351","600211","603658","688321","603567","688091","688137","688767","688656","600511","600080","688117","600079","601607","688336","688180","688276","600566","688488","600851","603456","688176","688278","600285","603108","603127","BK0188","605177","603309","688658","600529","600521","688161","600056","688687","600488","603590","688192","688373","688076","688235","688351","688578","BK0185","688114","159938"],"gpt_icon":0},{"id":"2486848738","title":"盟科药业：成功完成注射用MRX-4中国Ⅲ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2486848738","media":"格隆汇","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486848738?lang=zh_cn&edition=full","pubTime":"2024-11-27 17:09","pubTimestamp":1732698556,"startTime":"0","endTime":"0","summary":"格隆汇11月27日丨盟科药业公布，公司开展的注射用MRX-4转口服康替唑胺片治疗复杂性皮肤和软组织感染成人患者的中国Ⅲ期临床试验已于近日成功完成并达到了主要疗效终点。接受注射用MRX-4/康替唑胺片患者发生与研究药物相关的临床不良事件主要为胃肠道反应，包括恶心、呕吐等，与研究药物相关的实验室检查异常主要为肝酶轻度升高，多为轻度，且呈一过性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127171348a25957e6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127171348a25957e6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688373"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2022-08-05","address":"上海市浦东新区中国(上海)自由贸易试验区爱迪生路53号1幢1-4层101、2幢","stockEarnings":[{"period":"1week","weight":-0.0915},{"period":"1month","weight":0.0258},{"period":"3month","weight":0.4987},{"period":"6month","weight":0.2274},{"period":"1year","weight":-0.1677},{"period":"ytd","weight":-0.1485}],"companyName":"上海盟科药业股份有限公司","boardCode":"AI0027","perCapita":"27878股","boardName":"医药制造业","registeredCapital":"65521万元","compareEarnings":[{"period":"1week","weight":-0.007},{"period":"1month","weight":0},{"period":"3month","weight":0.2307},{"period":"6month","weight":0.1234},{"period":"1year","weight":0.154},{"period":"ytd","weight":0.1321}],"survey":"　　上海盟科药业股份有限公司是一家以治疗感染性疾病为核心，拥有全球自主知识产权和国际竞争力的创新药企业，致力于发现、开发和商业化针对未满足临床需求的创新药物。公司的主要产品为康替唑胺片。基于核心技术平台，公司持续推进已有项目的研发进度，完成了24项新化合物专利的申请。","serverTime":1734966461951,"listedPrice":8.16,"stockholders":"13116人(较上一季度增加1.76%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"盟科药业(688373)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供盟科药业(688373)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"盟科药业,688373,盟科药业股票,盟科药业股票老虎,盟科药业股票老虎国际,盟科药业行情,盟科药业股票行情,盟科药业股价,盟科药业股市,盟科药业股票价格,盟科药业股票交易,盟科药业股票购买,盟科药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"盟科药业(688373)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供盟科药业(688373)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}